THE EFFECTS NEUROPROTECTION OF TELMISARTAN ON STROKE WITH HYPERTENSION

Iin Ernawati, Hanik Badriyah Hidayati, Sumarno .
  MNJ, pp. 41-46  

Abstract


Stroke is the second deadly disease in the world after ischemic heart disease. According to data of RISKESDAS (Riset Kesehatan Dasar), stroke was the highest cause of death in Indonesia in 2013. Hypertension is the one of the most important risk factors for stroke. Hypertension therapy is done by modification and the use of antihypertensives. The antihypertensives used is Telmisartan which is a class of Angiotensin Receptor Blocker (ARB) that works by inhibiting bind to angiotensin II type receptors that is angiotensin II type 1 receptors (AT-1R) which directly make angiotensin II bind to AT-2R (angiotensin receptor type 2 receptors). Telmisartan has a neuroprotectant effect that works by inhibiting the appearance of inflammatory cytokines, production of ROS (Reactive Oxygen Species), PGE2 (prostaglandin E2) and NMDA (N-Methyl-D-Aspartate) activity. Telmisartan activates PPAR-gamma (PPAR-γ), which is very useful in carbohydrate and lipid metabolism which directly protect blood vessels. Telmisartan has the advantage of structure and pharmacokinetics that support the effects of nerve protection. Based on lipophilicity and chemical structure, Telmisartan easily penetrates the brain barrier and high affinity to PPAR-γ, supporting the effects of Telmisartan neuroprotection. Based on pharmacokinetic aspects, telmisartan has the advantage of having a rapid onset that ranges from 30-60 minutes, with T ½ (half life) elimination is 24 hours. T 1/2 elimination for up to 24 hours from Telmisartan is clinically beneficial to improve medication adherence.


Keywords


Telmisartan, Neuroprotection, stroke, antihypertensives

Full Text:

PDF

References


WHO, the top 10 causes of death fact sheet: updated January 2017. Avalaible from: http://www.who.int/mediacentre/factsheets/fs310/en/

Saenger, AK, Christenson, RH. Stroke biomarkers: progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem; 2010.56(1):21–33 DOI: 10.1373/clinchem.2009.133801

Raisa, N, Sujuti, H, Purnomo, H, Rahayu, M, Dalhar M. The influence of sampling time to serum glial fibrillary acidic protein (GFAP) levels in acute stroke. Malang Neurology Journal; 2019.5:30-33. DOI: 10.21776/ub.mnj.2019.005.01.

Villapol, S and Saavedra, JM. Neuroprotective Effects of Angiotensin Receptor Blockers, American Journal of Hypertension; 2015.28(3). DOI: 10.1093/ajh/hpu197

Kikuchi, K, Tancharoen, S, Ito, S. Review Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke, Int. J. Mol. Sci; 2013. 13: 18899-18924. DOI: 10.3390/ijms140918899

Cheung RTF. A Systematic Approach to the Definition of Stroke. Austin J Cerebrovasc Dis & Stroke; 2014.1:5;1024. Avalaible from: https://austinpublishinggroup.com/cerebrovascular-disease-stroke/fulltext/ajcds-v1-id1024.pdf

Sik Hong, K. Blood Pressure Management for Stroke Prevention and in Acute Stroke. Journal of Stroke; 2017.19(2):152-165. DOI: 10.5853/jos.2017.00164

Setianto, CA, Purnomo, H, Marhaendraputro, EA, Santoso, WM, Correlation Of C-Reactive Protein Levels With Clinical Outcome Intracerebral Hemorrhage Stroke Patients. Malang Neurology Journal; 2015;1(1):23-27. DOI: 10.21776/ub.mnj.2015.001.01.5

Chrismanita, A, Ong, Rizal, A. Hubungan antara Kejadian Hipertensi dengan Performa Fungsi Kognisi dan Gambaran Magnetic Resonance Imaging Kepala, Neurona; 2015. Vol 32 no. 2.

Kono, S, Kurata, T, Sato, K, Omote Y, Hishikawa N, Yamashita T, Deguchi K, Abe K. Neurovascular Protection by Telmisartan via Reducing Neuroinflammation in Stroke Resistant Spontaneously Hypertensive Rat Brain after Ischemic Stroke. “Journal of Stroke and Cerebrovascular Diseases”, Article in Press; 2014. 1-11. DOI: 10.1016/j.jstrokecerebrovasdis.2014.09.037

Sumners, C, Horiuchi, M, Widdop, R, McCarthy C, Unger T, Steckelings UM. Evolving Concepts of the Renin–Angiotensin System Protective arms of the renin–angiotensin-system in neurological disease, Clinical and Experimental Pharmacology and Physiology; 2013.40: 580–588. DOI: 10.1111/1440-1681.12137

Arroja, M, Reid, E, Mc Cabe, M. Review: Therapeutic potential of the rennin angiotensin system in ischaemic stroke, Experimental & Translational Stroke Medicine; 2016.8:8. DOI: 10.1186/s13231-016-0022-1

Burkey, K, Hoffmann, JC, Nemerovski, S. et al., Drug Information Handbook. A Clinically Relevant Resource for all healthcare Professionals. American Pharmacist Association, 24th Edition, Ohio: Lexi-Comp Inc; 2015.

Al Sabbah, Z, Mansoor, A, Kaul, U. Angiotensin Receptor Blockers - Advantages of the New Sartans, Journal of The Association of Physicians of India; 2013. Jul;61(7):464-70. Avalaible from: https://www.ncbi.nlm.nih.gov/pubmed/24772750

Michel, MC, Foster, C, Brunner, HR, Liu, L. A systematic comparison on the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev, 2013; 65:809–848. DOI: 10.1124/pr.112.007278

Benicky, J, Sánchez-Lemus, E, Honda, M, Pang T, Orecna M, Wang J, Leng Y, Chuang DM, Saavedra JM. Angiotensin II AT1 receptor blockade ameliorates brain inflammation. Neuropsychopharmacology; 2011.36:857–870. DOI: 10.1038/npp.2010.225

Pang, T, Wang, J, Benicky J, Sanchez-Lemus E, Saavedra JM. Telmisartan directly ameliorates the neuronal inflammatory response to IL-1β partly through the JNK/c-Jun and NADPH oxidase pathways. J Neuroinflammation; 2012.9:102 DOI: 10.1186/1742-2094-9-102

Wang, J, Pang, T, Hafko, R, Benicky J, Sanchez-Lemus E, Saavedra JM, Telmisartan ameliorates glutamate-induced neurotoxicity: roles of AT(1) receptor blockade and PPAR-γ activation”, Neuropharmacology; 2014.79:249–261. DOI: 10.1016/j.neuropharm.2013.11.022

Kakuta, H, Kurosaki, E, Niimi, T. Gato K, Kawasaki Y, Suwa A, Honbou K, Yamaguchi T, Okumura H, A Distinct Properties of Telmisartan on Agonistic Activities for Peroxisome Proliferator-Activated Receptor γ among Clinically Used Angiotensin II Receptor Blockers: Drug-Target Interaction Analyses”. J Pharmacol Exp Ther, 2014; 349:10-20. DOI: 10.1124/jpet.113.211722

Abraham, HM, White, M, White, W. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. Drug Saf; 2015. 38:1: 33. DOI: 10.1007/s40264-014-023


Refbacks

  • There are currently no refbacks.